Update on Covid I Ever since the Corona Virus outbreak, the medical pharma industry has been faced with an enormous challenge to study and create a cure or a vaccine for this virus. There is no doubt that the leading pharmaceutical companies are up for the challenge. Among them, Applied DNA Sciences Inc. in collaboration with Takis Biotech are two Pharma companies are close to developing a cure for COVID-19.
Applied DNA Sciences is the company that is always on the frontline with fighting the existing scientific hurdles of medical science with state-of-the-art research equipment. The company uses Next-generation sequencing Polymerase Chain Reaction (PCR) for DNA Manufacturing, product authenticity, traceability solutions, nucleic acid-based biotherapeutic development, and liquid biopsies for cancer diagnostics that allows the researchers to study DNA in detail and with efficiency.
Takis Biotech, an Italian pharmaceutical company that is collaborating with APDN is yet again an excellent research-based institution that was initiated by Merk Laboratories’ Researchers. The company has devoted its researchers to COVID-19 vaccine development. It already has a good reputation for developing vaccines for various diseases using DNA electro gene transfer for cancer immunotherapy and generating humanized monoclonal antibodies for use in Oncology and Infectious Diseases.
Both these companies have been working endlessly, using their resources collaboratively to develop the COVID-19 vaccine and they have recently announced that they have designed 4 preclinical designs based on spike protein structure for vaccines. The Spike protein basically allows the coronavirus to attach to the host cells and enable the virus to spread. Covid-19 is a rapidly mutative virus and hence constant surveillance is required for procuring its vaccine effects. It requires the Company’s proprietary PCR-based DNA manufacturing systems that help accelerate the process for vaccine development. The potential advantages of the PCR-produced Linear DNA vaccines include the spontaneous surveillance, efficiency and fast production with no antibiotics and bacterial contaminants, their resistance genes, purity of the DNA, the simplicity of design and the fact that the vaccine gene is effective without insertion into the patient’s genome make it a promising procedural approach for the Two companies to take for studying this highly mutative virus.
Presently the companies plan to use the scaled-up LinearDNA synthetic genes for each of the four putative vaccines to test on mice. Their samples will be tested for antibodies and whether they bind with the purified spike proteins to prevent virus spread. The ones that do bind will be analyzed for their efficiency in neutralizing COVID-19 by preventing the uptake of the virus in cells in culture and animal models.
However, Applied DNA and Takis both make it clear that no commercial partner has taken the coronavirus vaccine to market that’s identified. Furthermore, despite the PCR based systems the companies also do not have a clear indication that FDA or other regulators will approve the countermeasures suggested by the companies. I Update on Covid